Kiniksa Pharmaceuticals (KNSA) Revenue by Segment

Shows how revenue is distributed across different business segments, highlighting which areas are driving growth and which may need strategic adjustments.

ARCALYST’s product revenue has become the company's growth engine—steady, accelerating quarterly gains that prompted management to lift 2026 revenue guidance—while license/collaboration income has been episodic and effectively gone, meaning future revenue now hinges on commercial execution. That’s positive: rising prescriber penetration and the largest quarter-over-quarter increase since launch validate demand, but watch gross-to-net variability, persistent underdiagnosis limiting addressable reach, and rising operating costs that could compress margins despite strong top-line momentum.